Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multi-arm ceritinib study in ALK-altered advanced tumors (non-lung)
2015-000814-23Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ceritinib in Nonhematologic neoplasms and hematopoietic malignancies, sponsored by Novartis. Primary endpoint: Disease Control Rate (DCR). Started Jul 2015; status: terminated.
02
Drugs
ceritinib
03
Conditions
Nonhematologic neoplasmshematopoietic malignancies
Beyond the preview
Go deeper on 2015-000814-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000814-23.